BMS‐180448, A Glyburide‐Reversible Cardioprotective Agent with Minimal Vasodilator Activity

Grover, Gary J.; Atwal, Karnail S.

doi:10.1111/j.1527-3466.1995.tb00301.x

Cited by 7 publications

(2 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These data were confirmed in another study by the same investigators [44]. Pretreatment with BMS‐180448 had no effect on a decrease in subepicardial and subendocardial blood flow in the AAR (10 min) but increased myocardial blood flow in the AAR in reperfusion by about 1.5‐fold [100]. Diazoxide reduced infarct size in dogs with CAO and reperfusion but did not alter coronary blood flow in an ischemic region and did not affect reperfusion blood flow [92].…”

Section: Katp Channels Collateral Blood Flow No‐reflow Phenomenon And...supporting

confidence: 59%

“…Glibenclamide reversed this effect. It was demonstrated that pretreatment with BMS‐180448 promoted the recovery of contractile function of the dog heart at reperfusion after CAO in vivo [100]. A diazoxide‐induced improvement of contractile function of the isolated rat heart was abolished by glibenclamide or 5‐HD [59].…”

Section: Katp Channels and Cardiac Contractilitymentioning

confidence: 99%

See 1 more Smart Citation

K_ATP channels are regulators of programmed cell death and targets for the creation of novel drugs against ischemia/reperfusion cardiac injury

Maslov

Popov

Naryzhnaya

et al. 2023

Fundamemntal Clinical Pharma

View full text Add to dashboard Cite

BackgroundThe use of percutaneous coronary intervention (PCI) in patients with ST‐segment elevation myocardial infarction (STEMI) is associated with a mortality rate of 5%–7%. It is clear that there is an urgent need to develop new drugs that can effectively prevent cardiac reperfusion injury. ATP‐sensitive K+ (KATP) channel openers (KCOs) can be classified as such drugs.ResultsKCOs prevent irreversible ischemia and reperfusion injury of the heart. KATP channel opening promotes inhibition of apoptosis, necroptosis, pyroptosis, and stimulation of autophagy. KCOs prevent the development of cardiac adverse remodeling and improve cardiac contractility in reperfusion. KCOs exhibit antiarrhythmic properties and prevent the appearance of the no‐reflow phenomenon in animals with coronary artery occlusion and reperfusion. Diabetes mellitus and a cholesterol‐enriched diet abolish the cardioprotective effect of KCOs. Nicorandil, a KCO, attenuates major adverse cardiovascular event and the no‐reflow phenomenon, reduces infarct size, and decreases the incidence of ventricular arrhythmias in patients with acute myocardial infarction.ConclusionThe cardioprotective effect of KCOs is mediated by the opening of mitochondrial KATP (mitoKATP) and sarcolemmal KATP (sarcKATP) channels, triggered free radicals' production, and kinase activation.

show abstract

Section: Katp Channels Collateral Blood Flow No‐reflow Phenomenon And...supporting

confidence: 59%

Section: Katp Channels and Cardiac Contractilitymentioning

confidence: 99%

K_ATP channels are regulators of programmed cell death and targets for the creation of novel drugs against ischemia/reperfusion cardiac injury

Maslov

Popov

Naryzhnaya

et al. 2023

Fundamemntal Clinical Pharma

View full text Add to dashboard Cite

show abstract

ATP-Sensitive Potassium Channels: A Review of their Cardioprotective Pharmacology

Grover

Garlid

2000

Journal of Molecular and Cellular Cardiology

363

287

View full text Add to dashboard Cite

Therapeutic Potential of ATP-Sensitive K+ Channel Openers in Cardiac Ischemia

Grover

2001

Potassium Channels in Cardiovascular Biology

View full text Add to dashboard Cite

BMS‐180448, A Glyburide‐Reversible Cardioprotective Agent with Minimal Vasodilator Activity

Cited by 7 publications

References 29 publications

K_ATP channels are regulators of programmed cell death and targets for the creation of novel drugs against ischemia/reperfusion cardiac injury

K_ATP channels are regulators of programmed cell death and targets for the creation of novel drugs against ischemia/reperfusion cardiac injury

ATP-Sensitive Potassium Channels: A Review of their Cardioprotective Pharmacology

Therapeutic Potential of ATP-Sensitive K+ Channel Openers in Cardiac Ischemia

Contact Info

Product

Resources

About

BMS‐180448, A Glyburide‐Reversible Cardioprotective Agent with Minimal Vasodilator Activity

Cited by 7 publications

References 29 publications

KATP channels are regulators of programmed cell death and targets for the creation of novel drugs against ischemia/reperfusion cardiac injury

KATP channels are regulators of programmed cell death and targets for the creation of novel drugs against ischemia/reperfusion cardiac injury

ATP-Sensitive Potassium Channels: A Review of their Cardioprotective Pharmacology

Therapeutic Potential of ATP-Sensitive K+ Channel Openers in Cardiac Ischemia

Contact Info

Product

Resources

About

K_ATP channels are regulators of programmed cell death and targets for the creation of novel drugs against ischemia/reperfusion cardiac injury

K_ATP channels are regulators of programmed cell death and targets for the creation of novel drugs against ischemia/reperfusion cardiac injury